Active, not recruiting
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
NCT05396859
- Conditions
- Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
- Locations
-
- OHSU Knight Cancer Institute Portland, Oregon, United States